- Person suffering from corona virus successfully treated - new option for action in the pandemic
- Case generates keen interest in clinical circles
- CRP blood wash can also help conserve intensive care capacity
- Since bond issue: progress in expanding sales and customer base
Hennigsdorf, 27.01.2021 - Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB) operating in the dynamically growing healthcare sector, has successfully treated a patient suffering from COVID-19 caused by the corona virus with its CE-certified and patent-protected medical product PentraSorb® CRP. The company has thus created another important option for action in the fight against the often fatal effects of the pandemic. The extracorporeal, virtually risk-free CRP apheresis saved the COVID-19 patient from intensive care ventilation and its consequences, as well as damage to the lungs, heart and other organs.
The case has generated keen clinical interest, especially as hospitals in Germany are overloaded due to the Corona pandemic. Virtually all of the drug therapies used to date can be classified as only partially effective in individual cases or even as failures. According to physicians, reasonable therapy strategies are not available. For example, the two new antibody-based Corona drugs recently ordered by the German government from the U.S. pharmaceutical company Eli Lilly have so far only been tested on small groups of patients in the United States. In addition, according to the Federal Ministry of Health, these drugs have not yet been approved by the European Medicines Agency (EMA).
Now also used against COVID-19: PentraSorb® as the world's only therapy for CRP blood washing
In the case of corona disease, as in other applications, Pentracor's PentraSorb® CRP extracorporeally filters the excessively produced endogenous protein CRP from the patient's blood. This blood wash prevents the protein CRP from increasing in the body due to the inflammatory response triggered by the corona virus and indirectly causing long-term damage to organs. Pentracor CEO Ahmed Sheriff: "It is not the virus that destroys the lungs, but rather the inflammation caused by the viral infection. The CRP level in the blood then rises very quickly. This fulminant increase does not even occur if our CRP filter is used in time."
The Pentracor GmbH offers with its medical product PentraSorb® CRP a new therapeutic, extracorporeal treatment method. This is used primarily to sustainably curb progressive internal tissue damage in patients after acute events such as myocardial infarction and stroke. Research in this area began in 2003 at the university level. PentraSorb® CRP is CE-certified, patent-protected and reimbursed by all health insurance companies in Germany. Ahmed Sheriff: "PentraSorb® CRP has sustainable benefits for all parties involved: for patients whose lives can be saved or where partial organ insufficiencies can be contained. Likewise, the treating physicians, hospitals or outpatient clinics, and the health care system benefit, since chronic organ insufficiencies that require continuous follow-up treatment at great expense can be prevented. In the case of COVID-19, hospitals could be significantly relieved. Moreover, the patients would not have to deal with consequential damage, or would have to do so to a much lesser extent. In addition, deaths would very likely be reduced."
Multiple applications in the growing healthcare market
PentraSorb® CRP is not subject to any restrictions of use for specific disease patterns, as is, on the other hand, indispensable for drugs for each individual field of application. For example, CRP apheresis can also be used for stroke patients and rheumatic diseases. In the EU, the blood wash filter is patent-protected. It is used outside the body in combination with conventional dialysis-type systems. In the indicated cases, it filters the harmful so-called C-Reactive Protein (CRP) from the blood plasma. Further flanking patents in the relevant markets in the United States of America and Asia have been granted. PentraSorb® CRP has been fully approved as a CE-certified medical device since November 2014. It has been reimbursed by all health insurance companies in Germany since 2018 and has been in use since then.
Since the bond issue and the listing on the Frankfurt Stock Exchange at the end of May 2020, Pentracor GmbH has focused on expanding sales and broadening its customer base. Despite the Corona-related limitations, especially in the dialogue with clinics and hospitals, the company has made good progress.
Über die Pentracor GmbH
Pentracor GmbH, a spin-off from the university environment, was founded in 2010. With the solution PentraSorb® CRP, a completely new therapeutic, extracorporeal treatment method is offered with a unique selling proposition to sustainably contain progressive internal tissue damage in patients after acute events such as myocardial infarction or stroke. By filtering the blood plasma outside the body, the so-called C-Reactive Protein (CRP), which causes tissue damage, is selectively removed. Pentracor has extensive and patent-protected know-how regarding the use and production of the adsorber PentraSorb® CRP. Apheresis with Pentracor's medical device PentraSorb® CRP is the only therapy available worldwide that can selectively lower CRP levels in the body, resulting in better treatment outcomes for acute events such as heart attacks. PentraSorb® CRP has been fully approved as a CE-certified medical device since 2014 and has been reimbursed by all health insurance companies in Germany by means of an additional charge since November 2018.
[wptb id="3002" not found ]Selected article on the topic
